文献速递头颈外科

免疫检查点抑制剂作为晚期头颈癌的一线治疗

Immune Checkpoint Inhibitors Serve as the First-Line Treatment for Advanced Head and Neck Cancer.
PubMed 文献 · Laryngoscope · 2023-08-23

该网络Meta分析纳入19项随机对照试验共5900例患者,比较14种免疫治疗方案作为晚期头颈癌一线治疗的疗效与安全性;帕博利珠单抗联合化疗在总生存期和客观缓解率方面最优,特瑞普利单抗联合化疗在延长无进展生存期方面可能性最高,度伐利尤单抗不良事件概率最低。

要点

  • 帕博利珠单抗联合化疗在总生存期和客观缓解率方面为最有前景的一线方案。
  • 特瑞普利单抗联合化疗成为延长无进展生存期首选治疗的可能性最高。
  • 度伐利尤单抗不良事件概率最低;卡瑞利珠单抗联合化疗不良事件风险升高。

核心结论

  • 分析提示将化疗药物与免疫检查点抑制剂联合可增强其作为晚期头颈癌患者一线治疗的疗效。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane数据库截至2023年6月10日发表的随机临床试验,纳入免疫检查点抑制剂单药或联合治疗并报告治疗相关不良事件的试验,采用贝叶斯随机效应模型进行网络Meta分析,共纳入19项随机对照试验、涉及5900例患者、14种治疗方案。

主要发现

  • 帕博利珠单抗联合化疗在总生存期和客观缓解率方面为最有前景的一线治疗。
  • 特瑞普利单抗联合化疗成为延长无进展生存期首选治疗的可能性最高。
  • 度伐利尤单抗不良事件概率最低,提示较其他药物更安全。
  • 卡瑞利珠单抗联合化疗不良事件风险升高。
  • 双免疫检查点抑制剂纳武利尤单抗/伊匹木单抗在客观缓解率和不良事件方面优于度伐利尤单抗/替西木单抗;标准治疗方案在四项结局指标上未表现出强劲性能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitor (ICI) therapy has demonstrated substantial benefits for certain patients. We try to evaluate the merits and demerits of each immunotherapy to aid clinical treatment. METHODS: We conducted a comprehensive search of the PubMed, Embase, and Cochrane databases for randomized clinical trials published as of June 10, 2023. Our study included published clinical trials of ICI monotherapy or combination therapy, along with data on treatment-related adverse events (TRAE). Data regarding survival efficacy and adverse events of each randomized controlled trial (RCT) were collected. The Bayesian random effects model was utilized for the network meta-analysis (NMA). RESULTS: This study incorporated 19 RCTs, involving 5900 patients. Among 14 treatment regimens, Pembrolizumab combined with chemotherapy emerged as the most promising primary treatment for overall survival (OS) and objective response rate (ORR). Toripalimab combined with chemotherapy exhibited the highest likelihood of becoming the primary treatment for extending progression-free survival (PFS). Durvalumab showed the lowest probability of adverse events, suggesting a safer profile compared with other drugs. Camrelizumab combined with chemotherapy demonstrated a heightened risk of adverse events. Dual ICI Nivolumab/Ipilimumab surpassed Durvalumab/Tremelimumab in terms of ORR and adverse events. The standard of care (SOC) regimen did not exhibit strong performance across the four outcome indicators. CONCLUSION: Our analysis suggests that the integration of chemotherapy agents with ICIs enhances its efficacy as a first-line treatment for patients with advanced head and neck cancer (HNC). LEVEL OF EVIDENCE: 1 Laryngoscope, 134:749-761, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Huang Y, Zhou H, Zhao G, et al. Immune Checkpoint Inhibitors Serve as the First-Line Treatment for Advanced Head and Neck Cancer. Laryngoscope. 2023. PMID: 37610169. doi:10.1002/lary.30971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。